**Purpose:** Since the detection of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) among humans in 2012, questions remain unanswered regarding the virus\'s origins; clinical, epidemiological, and virological characteristics; and potential therapeutics. A systematic literature review was conducted to synthesize current knowledge and identify critical knowledge gaps.

**Methods & Materials:** We conducted a systematic review on MERS-CoV using PRISMA guidelines and identified 312 relevant, peer-reviewed publications from Embase, Google Scholar, and PubMed. Of these, 206 were selected for inclusion based on their contributions to four pre-defined themes (virology, epidemiology/clinical characteristics, origins/reservoirs, and therapeutics/prevention).

**Results:** Virological research identified the functional human receptor (CD26/DPP4) and shed light on MERS-CoV\'s broad species tropism. A variety of molecular and serological assays have been developed for surveillance and research. The epidemiologic profile is incomplete, although initial data suggest values for the basic reproductive rate, proportion of primary cases, case fatality rate, and demographic and geographic distributions. There have been sustained outbreaks in Saudi Arabia and South Korea, and potential risks for infection include camel contact, nosocomial exposures, and close contact to active cases, but not Hajj pilgrimage. The primary mechanism of transmission in health care settings appears to be environmental contamination of medical devices and surfaces from respiratory secretions. MERS and MERS-like CoVs have been detected in bat species in numerous countries, and MERS-CoV is genetically similar to bat coronavirus HKU-4, which contains cell surface-expressed CD26/DPP4. Dromedary camels have demonstrated MERS-CoV seropositivity throughout the Middle East and Africa and there is preliminary evidence of camel-to-human MERS-CoV transmission events. Various potential therapeutic agents have been identified from high-throughput screening and other methods, but none have been clinically evaluated in human trials. At least one candidate vaccine has progressed to Phase I human trials.

**Conclusion:** Although there has been substantial MERS-CoV research since 2012, significant knowledge gaps persist. Uncertainties remain about the zoonotic origin, clinical characteristics, risk factors for infection, asymptomatic transmission, effective therapeutics, and vaccine candidates. These areas merit urgent attention by the global community to better understand, detect, and control MERS-CoV using a unified One Health approach.
